Chester County News and Community Website
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network has issued its first clinical guidelines specifically for pediatric bone sarcoma, establishing treatment recommendations for Ewing sarcoma and related rare cancers …
NCCN Adds Pediatric Guidelines for Rare Bone Cancer Read More
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. secured a $3.17 million, five-year National Cancer Institute grant to advance an experimental radiopharmaceutical toward potential clinical testing in patients with non-small …
MTTI Lands $3.17 Million NCI Grant to Advance Lung Cancer Drug Read More
WASHINGTON, D.C. — U.S. cancer death rates declined for both men and women from 2019 through 2023, extending a more than two-decade drop driven largely by faster progress against lung …
Lung Cancer Gains Push U.S. Cancer Death Rates Lower Read More
CHESTERBROOK, PA — Persevere Therapeutics has dosed the first patient in a Phase 2a trial of misetionamide at the University of Pennsylvania’s Abramson Cancer Center, moving the experimental MYC inhibitor …
Persevere Begins Phase 2a Ovarian Cancer Trial at Penn Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network has released new patient guidelines for adults 65 and older, emphasizing health, cognition, and physical function rather than chronological age alone …
NCCN Expands Cancer Guidance for Patients Over 65 Read More
WILMINGTON, DE — AstraZeneca (NYSE: AZN) and Daiichi Sankyo’s Enhertu extended median progression-free survival by six months versus pembrolizumab plus chemotherapy in a Phase III trial of first-line treatment for …
Enhertu Extends PFS by Six Months in HER2 Lung Cancer Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) Tagrisso showed a sustained survival benefit eight years after treatment in a Phase III trial of patients with early-stage EGFR-mutated non-small cell lung cancer, …
Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial Read More
PLYMOUTH MEETING, PA — Every cancer center responding to a National Comprehensive Cancer Network survey reported at least one anti-cancer drug shortage in late August, extending a supply problem that …
Cancer Drug Shortages Persist at Major U.S. Centers Read More
PHILADELPHIA, PA — Fore Biotherapeutics will continue its FORTE study of plixorafenib as planned after an independent monitoring committee cleared the first interim efficacy analysis of its BRAF fusion cohort, …
Fore Bio Clears Interim Review in BRAF Fusion Cancer Study Read More
WASHINGTON, D.C. — The Food and Drug Administration approved Revolution Medicines Inc.’s Rasonque for certain adults with metastatic pancreatic adenocarcinoma after a clinical trial showed the drug nearly doubled median …
FDA Approves Rasonque as Pancreatic Cancer Treatment Read More